Belimumab Pregnancy Safety LN — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Stop mycophenolate and plan a specialist preconception treatment transition
The best answer is “Stop mycophenolate and plan a specialist preconception treatment transition”. Preconception planning requires stable disease and pregnancy-compatible immunosuppression. Mycophenolate must be replaced under specialist supervision, and the belimumab SmPC requires contraception for 4 months after the final dose. “Continue hydroxychloroquine while replacing pregnancy-incompatible immunosuppression” is less appropriate because mycophenolate is teratogenic and belimumab has a defined post-treatment contraception interval “Continue mycophenolate until pregnancy is biochemically confirmed” is less appropriate because hydroxychloroquine is generally maintained while mycophenolate requires substitution “Stop belimumab according to specialist preconception risk assessment” is less appropriate because preconception avoidance is required rather than late-pregnancy withdrawal “Increase belimumab before conception to reduce future flare risk” is less appropriate because dose escalation does not address fetal-exposure uncertainty
Reference: Benlysta Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/11398/smpc